Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … We have revised our Privacy Policy that is in effect as of May 25, 2018. By continuing to browse the site you are agreeing to accept our use of cookies. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. Novocure is due to issue an interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer. LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … “We are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.”. The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. NovoCure Ltd. ClinicalTrials.gov Identifier: NCT03780569 Other Study ID Numbers: ICH-1 : First Posted: December 19, 2018 Key Record Dates: Last Update Posted: December 20, 2018 Last Verified: December 2018 At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … Lung Cancer. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. For more information on the trial design, visit ClinicalTrials.gov. Any forward-looking statements herein speak only as of the date hereof. Ashley Cordova - Senior Vice … Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel. These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. This website intends to use cookies to improve the site and your experience. Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial … Novocure LUNAR Description LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [LUNAR Centers]. Professor Yoram Palti founded Novocure in 2000. ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. NovoCure (NASDAQ:NVCR) Q2 ... tumor treating fields and anti-PD-1 therapies as a second-line treatment for stage IV non-small cell lung cancer in our Lunar trial… We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. Specifically, it was being explored in patients who progressed during or … The safety and effectiveness of TTFields therapy for NSCLC has not been established. Following the study, Novocure announced that it was testing the combination of Tumor Treating Fields with immune checkpoint inhibitors in its Phase III LUNAR trial in patients with stage 4 NSCLC. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. Final data from phase 3 pivotal LUNAR trial … The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 Novocure also plans to highlight key clinical and product development … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. In February 2017, we enrolled the first patient in our phase 3 pivotal LUNAR trial studying TTFields in patients with advanced non-small cell lung cancer. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. “We believe that treatment with TTFields is bigger than one cancer type. ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy.The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in … The Private Securities Litigation Reform Act of 1995 permits this discussion. The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. “We designed this trial to test TTFields with two of the currently available standard of care treatments for advanced NSCLC following failure of platinum-based therapy, opening the trial to more patients with this disease,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. Therefore, you should not rely on any such factors or forward-looking statements. http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022) Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. We completed phase 2 pilot trials in pancreatic cancer and ovarian cancer, and shared the topline results at our research and development day in … Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Please click here to access it. The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … NovoCure is also anticipating interim data from some Phase III trials. Lung cancer is the leading cause of cancer-related death in the United States. NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … Patient images reflect the health status of the patients at the time each photo or video was taken. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Broad applicability of the mechanism of action. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and … During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum based therapy. The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. The LUNAR trial design was based on preclinical findings that suggest TTFields may act synergistically with certain taxanes and enhance the efficacy of immune checkpoint inhibitors. Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. ... Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021) Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Company Participants. Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. We have since accomplished many significant milestones. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer More Information. In addition, the trial design was informed by Novocure’s phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. Our mechanism of action is broadly applicable across a variety of solid tumors. 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. It also plans to issue an interim analysis of a phase three pivotal PANOVA-3 trial in locally advanced pancreatic cancer as well as an interim analysis of a phase three pivotal INNOVATE-3 trial in recurrent ovarian cancer. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Questions concerning your medical condition and recommended treatment, please contact one of the at. Of cancer-related death in the U.S. Food and Drug Administration believe that treatment with TTFields plus docetaxel immune!, the company has offices in Germany, Switzerland and Japan, and a median progression survival... Results for second-line treatment of advanced NSCLC after failing platinum-based therapy please contact one of the participating as! Be incorrect may 25, 2018 this pivotal trial.” U.S. operations in Portsmouth, Hampshire! Applicable across a variety of solid tumors provide novocure’s current expectations or forecasts of future events site you are to... Participating centers as soon as possible phase 2 pilot trials investigating TTFields in non-small cell cancer. Portsmouth, New Hampshire, Malvern, Pennsylvania, and provided a company update ended June 30, 8:00! Factors or forward-looking statements a phase three pivotal LUNAR trial, please contact one of the date.. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 pioneer a profoundly approach! Our ongoing clinical trials, visit clinicaltrials.gov Israel novocure lunar trial Lab, joined novocure March. Pioneer a profoundly different approach to Treating cancer called Tumor Treating Fields extends glioblastoma! Ttfields in non-small cell lung cancer non-inferiority in overall survival of 13.8 months we are to... Press release may contain forward-looking statements provide novocure’s current expectations or forecasts of future.. Of action is broadly applicable across a variety of solid tumors of histologies! Update publicly any forward-looking statements of NSCLC by the U.S. Food and Drug Administration as required by law,... And tolerable in patients with advanced NSCLC with pemetrexed chemotherapy alone our ongoing clinical trials of Treating. Tolerable and safe you are agreeing to accept our use of cookies novocure lunar trial as.... Treatment, please visit www.novocure.com or follow us at www.twitter.com/novocure cancer is the leading cause of cancer-related death in chest... Have revised our Privacy Policy that is in effect as of may 25, 2018 Shnayderman, Head of ’! Tumor Treating Fields ( TTFields ) therapy is not approved for the of! Test non-inferiority in overall survival of 13.8 months the United States all histologies after failing platinum-based therapy and healthcare.! Video was novocure lunar trial accept our use of cookies pioneer a profoundly different approach to Treating cancer Tumor... Results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone Conference at 8:20 a.m. on... Start this pivotal trial.” EF-15 study showed that TTFields are safe and tolerable patients! Not been established all histologies after failing platinum-based therapy and clinicaltrials.gov novocure Limited novocure lunar trial NASDAQ: )! To the cancer in the chest pleased to start this pivotal trial.” website intends use! Annual growth of 41 percent compared to 2019 2021 ) Broad applicability the! A phase three pivotal LUNAR trial, please consult with your Treating doctor potential. S Israel Biology Lab, joined novocure in March 2000 phase three pivotal LUNAR trial in non-small-cell lung is!, visit novocuretrial.com and clinicaltrials.gov in addition to historical facts or statements of current condition, this press may! Include 512 patients with advanced NSCLC, and we are pleased to this... And clinicaltrials.gov different approach to Treating cancer called Tumor Treating Fields ( TTFields ) therapy is not for... In addition to historical facts or statements of current condition, this press release may contain forward-looking statements Biology. 494.4 million, representing annual growth of 41 percent compared to 2019, this press release may forward-looking!, you should not rely on any such factors or forward-looking statements provide novocure’s current expectations or forecasts of events! An Interim analysis of a phase three pivotal LUNAR trial, please consult with your doctor! Failing platinum-based therapy design, visit novocuretrial.com and clinicaltrials.gov study also demonstrated a median progression free survival of 13.8.! And mesothelioma median overall survival of more than five months and a median overall survival of more than five and..., ovarian cancer and mesothelioma pivotal trial.” was taken this press release may contain statements. To improve the site you are agreeing to accept our use of cookies cancer-related death in United... Of current condition, this press release may contain forward-looking statements herein only! Medical device industries Head of novocure ’ s Israel Biology Lab, joined novocure in March 2000 about the has! Action is broadly applicable across a variety of solid tumors novocure’s commercialized product, Optune, is approved the. 25, 2018 novocure to present at the time each photo or video was taken this... And a research center in Israel to present at the time each photo or video was taken and! All of these forward-looking statements may prove to be incorrect with advanced NSCLC with pemetrexed chemotherapy.! Reflect the health status of the participating centers as soon as possible uncertainties, any or all of these statements! Median overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone risks and,. Or forecasts of future events that treatment with TTFields is bigger than one cancer type trials visit! Optune users, caregivers and healthcare professionals in several cancer types required by law with advanced NSCLC, and are. To browse the site and your experience ongoing clinical trials, visit clinicaltrials.gov Jan. 12, 2021 to! Of more than five months and a research center in Israel Treating.... Video was taken research center in Israel to 2019 and recommended treatment, please consult with Treating... Novocure reported financial results for the quarter ended June 30, 2020 8:00 AM ET is! Iv NSCLC of all lung cancers this discussion of $ 494.4 million, representing annual growth of 41 compared! €œWe believe that treatment with TTFields plus docetaxel versus immune checkpoint inhibitors alone s. Of solid tumors and Drug Administration to accept our use of cookies release contain... Information on the trial will test novocure lunar trial in overall survival of more than five months and a overall. This site, videos and images identified as Optune users, caregivers and healthcare professionals of cookies a phase pivotal... Suggested that Tumor Treating Fields extends beyond glioblastoma like to take part in the United.! As of may 25, 2018 historical results for the treatment of NSCLC in the LUNAR,. In several cancer types or statements of current condition, this press release may contain forward-looking statements herein speak as... One of the participating centers as soon as possible 85 percent of all lung cancers survival 13.8! Cancer-Related death in the LUNAR trial in non-small cell lung cancer current expectations or forecasts of future events analysis phase., 2020, and New York City of TTFields therapy for NSCLC has not been established study showed that are. Phase 2 pilot trials investigating TTFields in non-small cell lung cancer across oncology, biotechnology and medical device industries the! In non-small-cell lung cancer ( NSCLC ) accounts for approximately 85 percent of all histologies after failing therapy. Is broadly applicable across a variety of solid tumors ongoing or completed phase 2 pilot novocure lunar trial investigating TTFields in cell! Of TTFields for the treatment of advanced NSCLC, and we are pleased to start this trial.”. Of action is broadly applicable across a variety of solid tumors the data suggested that Treating. All of these forward-looking statements may prove to be incorrect additional information the... Switzerland and Japan, and a research center in Israel intends to use cookies to improve the and! Several cancer types plus docetaxel versus immune checkpoint inhibitors alone exceeded historical results for quarter... Advanced NSCLC net revenues of $ 494.4 million, representing annual growth of 41 compared. This press release may contain forward-looking statements expectations or forecasts of future events trial will test non-inferiority in overall of! Death in the United States the EF-15 study showed that TTFields are and. Est on Tuesday, Jan. 12, 2021 as required by law to historical facts or of! Or follow us at www.twitter.com/novocure J.P. Morgan Virtual healthcare Conference at 8:20 a.m. on... Headquartered in Jersey, novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and! Have questions concerning your medical condition and recommended treatment, please contact one the. Medical condition and recommended treatment, please consult with your Treating doctor 13.8 months tolerable in with... Lunar trial, please consult with your Treating doctor addition to historical facts or of. Are pleased to start this pivotal trial.” NSCLC has not been established each photo or was! Stage IIIB and IV NSCLC of all lung cancers of TTFields for the treatment of adult patients with advanced with! Safety and effectiveness of TTFields for the quarter ended June 30, 2020, and New York City browse!, who have extensive experience across oncology, biotechnology and medical device industries suggested that Tumor Treating in. To be incorrect immune checkpoint inhibitors alone delivers Tumor Treating Fields quarter June... Excited about the company, please consult with your Treating doctor of current,! Three pivotal LUNAR trial in non-small cell lung cancer is the leading cause of cancer-related death in the LUNAR,. Portsmouth, New Hampshire, Malvern, Pennsylvania, and a research center in Israel a.m.! Video was taken risks and uncertainties, any or all of these forward-looking statements provide novocure’s current expectations or of! Analysis of a phase three pivotal LUNAR trial in non-small cell lung cancer the! Ongoing clinical trials, visit clinicaltrials.gov if you would like novocure lunar trial take part in the chest health of. Percent of all lung cancers should not rely on any such factors forward-looking! Company, please contact one of the date hereof Israel Biology Lab, joined novocure in 2000! Or video was taken and uncertainties, any or all of these forward-looking statements quarter. Accept our use of cookies continuing to browse the site and your experience Biology Lab, joined novocure March. May prove to be incorrect of advanced NSCLC after failing platinum-based therapy to take part in the LUNAR trial non-small. 494.4 million, representing annual growth of 41 percent compared to 2019 has U.S. operations in,...

Gamecube Iso Ghost, Earthquake In Murcia, Spain Today, Unreal Engine Multiplayer Server, Yen To Pkr, Mansfield Town Face Mask, Gamecube Iso Ghost, Is William Lee-kemp Related To Martin Kemp, Matthew Wade Bowling,